Our LA Cell partnership with City of Hope National Medical Center in Duarte, California will focus on the development of groundbreaking cell-internalizing antibody therapies. The newly formed company combines City of Hope’s cell- internalizing technology with Sorrento’s fully human antibody library and immunotherapy expertise to enable the development of effective antibody therapies against elusive intracellular targets.

Antibodies Against Intracellular Targets

LA Cell has exclusively licensed technology developed at City of Hope to enable modified monoclonal antibodies (mAbs) to penetrate into cells and target previously “undruggable” disease-causing proteins. The technology is based on a proprietary chemical modification of mAbs that allows the modified mAb penetrating into the cell while maintaining their ability to binding to specific target proteins. This novel cell-internalizing technology could be transformative for the field of biomedical research and biopharmaceutical development.

The ability to harness the inherent target specificity of antibodies against disease-causing molecules inside the cell could lead to the next generation of therapies against many severe diseases. Utilizing mAbs derived from Sorrento’s antibody portfolio, LA Cell is positioned to develop therapies against important oncology targets. The technology can also be applied to medically-relevant targets in other indications, such as inflammation, auto-immune disorders, diabetes, central nervous systems (CNS), cardiovascular diseases, and viral infections.

“With LA Cell, we believe we have added the last missing piece in Sorrento’s portfolio of comprehensive antibody technologies. We can now develop a wide variety of antibody-based therapies no longer restricted by the antigen location.”
– Dr. Henry Ji, CEO